

To: Berg, A. (Angelique) [(10)(2e)]@minvws.nl]
From: [(10)(2e)]
Sent: Thur 6/11/2020 5:32:54 PM
Subject: FW: Compliance & indemnity
[AZ Europe - MK 6-11 REDLINE MP.docx](#)

Alvast reflectie kpmg tkn

Van: [(10)(2e)] <[(10)(2e)]@kpmg.nl>
Verzonden: donderdag 11 juni 2020 18:45
Aan: [(10)(2e)] <[(10)(2e)]@minvws.nl>; [(10)(2e)] <[(10)(2e)]@hoyngrokh.com>
CC: [(10)(2e)] <[(10)(2e)]@minvws.nl>; [(10)(2e)] <[(10)(2e)]@minvws.nl>
Onderwerp: RE: Compliance & indemnity

[(10)(2e)]

Dank in het document twee opmerkingen. Onderstaand 2 is een risico. Graag ook de input van [(10)(2e)] daarop.

[(10)(2a)]

Groet

[(10)(2e)]

T [(10)(2e)] | **M** [(10)(2e)]
 [(10)(2e)] <[(10)(2e)]@kpmg.nl> | www.kpmg.nl
 KPMG | Laan van Langerhuize 1, 1186 DS Amstelveen

KPMG Advisory N.V., handelsregisternummer 33263682

<https://preference.kpmg.nl/>

From: [(10)(2e)] <[(10)(2e)]@minvws.nl>
Sent: donderdag 11 juni 2020 18:25
To: [(10)(2e)] <[(10)(2e)]@hoyngrokh.com>; [(10)(2e)] <[(10)(2e)]@kpmg.nl>
Cc: [(10)(2e)] <[(10)(2e)]@minvws.nl>; [(10)(2e)] <[(10)(2e)]@minvws.nl>
Subject: FW: Compliance & indemnity

Hallo [(10)(2e)], [(10)(2e)] dit keer binnen een minuut

Graag jullie finale duiding ten behoeve van ons besluit dit mogelijk te doen, bij voorkeur in komende uur
 Dank

Van: [(10)(2e)] <[(10)(2e)]@pm.gouv.fr>
Verzonden: donderdag 11 juni 2020 18:23
Aan: Berg, A. (Angelique) <[(10)(2e)]@minvws.nl>; [(10)(2e)] <[(10)(2e)]@pm.gouv.fr>;
 [(10)(2e)] <[(10)(2e)]@unicatt.it>; [(10)(2e)] -RL 117 BMG <[(10)(2e)]@bmg.bund.de>
CC: [(10)(2e)] (IGF) <[(10)(2e)]@igf.finances.gouv.fr>; [(10)(2e)] <[(10)(2e)]@minvws.nl>; [(10)(2e)]
 [(10)(2e)] <[(10)(2e)]@minvws.nl>
Onderwerp: TR: Compliance & indemnity

Dear All

Latest version from AZ [(10)(2a)]
 Please could you



De : (10)(2e) <(10)(2e)@astrazeneca.com>

Envoyé : jeudi 11 juin 2020 17:55

À : (10)(2e) <(10)(2e)@cabinets.finances.gouv.fr>; (10)(2e) <(10)(2e)@astrazeneca.com>; (10)(2e)

<(10)(2e)@astrazeneca.com>; (10)(2e) <(10)(2e)@astrazeneca.com>

Cc : (10)(2e) <(10)(2e)@pm.gouv.fr>; (10)(2e) <(10)(2e)@gide.com>; (10)(2e)

<(10)(2e)@igf.finances.gouv.fr>; (10)(2e) (CAB/SANTE) <(10)(2e)@sante.gouv.fr>

Objet : RE: Compliance & indemnity

Dear (10)(2e) et. al.,

Further to our discussion of this afternoon, please find enclosed the final draft document reflecting all changes discussed. While the document currently goes through internal approval, we already send you a clean document as well as the document with redline against the version I have sent you this morning.

Please let me know if you agree the final changes made.

With best regards,

(10)(2e)

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

T: (10)(2e) | M: (10)(2e)

(10)(2e) @astrazeneca.com

Geschäftsführer: Dr. (10)(2e)

(10)(2e)

Handelsregister: AG Pinneberg HRB 5069

www.astrazeneca.de
www.astrazeneca.com

From: (10)(2e)

Sent: 11 June 2020 10:12

To: (10)(2e) <(10)(2e)@cabinets.finances.gouv.fr>; (10)(2e) <(10)(2e)@astrazeneca.com>; (10)(2e)

<(10)(2e)@astrazeneca.com>; (10)(2e) <(10)(2e)@astrazeneca.com>

Cc: (10)(2e) <(10)(2e)@pm.gouv.fr>; (10)(2e) <(10)(2e)@gide.com>; (10)(2e) <(10)(2e)@igf.finances.gouv.fr>;

(10)(2e) (CAB/SANTE) <(10)(2e)@sante.gouv.fr>

Subject: RE: Compliance & indemnity

Dear all,

Following our constructive discussion of yesterday, we have made several changes in the document to accommodate as much as

possible your requests (please see attachment).

Looking forward to our meeting at 12:30. Since we have only 30 min, we would highly appreciate to receive any comments from your side in advance to the meeting.

Best regards,

(10)(2e)

(10)(2e)

AstraZeneca GmbH

Tinsdaler Weg 183, 22880 Wedel

T: (10)(2e) | M: (10)(2e)

(10)(2e) @astrazeneca.com

Geschäftsführer: Dr. (10)(2e)

(10)(2e)

Handelsregister: AG Pinneberg HRB 5069

From: (10)(2e) <(10)(2e)@cabinets.finances.gouv.fr>

Sent: 10 June 2020 19:00

To: (10)(2e) <(10)(2e)@astrazeneca.com>; (10)(2e) <(10)(2e)@astrazeneca.com>; (10)(2e)

<(10)(2e)@astrazeneca.com>; (10)(2e) <(10)(2e)@astrazeneca.com>

Cc: (10)(2e) @pm.gouv.fr; (10)(2e) @gide.com; (10)(2e) <(10)(2e)@igf.finances.gouv.fr>;

(10)(2e) <(10)(2e)@sante.gouv.fr>

Subject: Compliance & indemnity

CAUTION: This email originated outside AstraZeneca. Do not open the attachment(s) unless you recognize the sender and know the content is safe.

Dear all,

Pursuant our discussions with (10)(2e), please find enclosed a revised wording regarding compliance and indemnity, for discussion in a few minutes.

(10)(2e)

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.
This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com

The information in this e-mail (and any attachments) is intended exclusively for the addressee(s). Any use by a party other than the addressee(s) is prohibited. The information may be confidential in nature and fall under a duty of non-disclosure. If you are not the addressee, please notify the sender and delete this e-mail. KPMG cannot guarantee that e-mail communications are secure and error-free and does not accept any liability for damages resulting from the use of e-mail. Our services and other work are carried out under an agreement of instruction (overeenkomst van opdracht) that is subject to the general terms and conditions of the contracting KPMG firm. These general terms and conditions are available on our website (www.kpmg.nl/algemenevoorwaarden) and will be forwarded upon request. Agreements with and statements from KPMG are only legally binding upon KPMG if they are confirmed in writing and signed by an authorized person.
